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Introduction
Due to unfavorable molecular size and lipophilicity,
migraine-specific medications such as dihydroergotamine
(DHE) are not expected to penetrate the blood-brain
barrier (BBB). A breakdown of the BBB during migraine
attacks has been postulated as the mechanism in which
DHE accesses postulated central sites of action.
Aim
To demonstrate whether the permeability of the BBB
increases for DHE during migraine attacks.
Methods
As a measure of parenchymal binding in the brain and
thus BBB penetration, we calculated the influx rate con-
stant Ki for the radioligand [11C]-dihydroergotamine
([11C]-DHE) using arterial blood input function over the
course of dynamic positron emission tomography (PET).
The influence of migraine on the Ki maps, i.e. the BBB
was assessed in a second [11C]-DHE scan during glyceryl
trinitrate (GTN)-induced migraine attacks.
Results
Independent from the presence of migraine headache, six
migraineurs and six age- and gender-matched control
subjects showed identical binding of [11C]-DHE at the
choroid plexus, the pituitary gland, and the venous
sinuses. There was no binding (Ki = 0/min) in the brain
parenchyma, including the candidate brainstem sites of
action during migraine (periaqueductal grey, raphe
nuclei) and the area with the highest density of the
highest-affinity DHE receptors (hippocampus).
Conclusions
The lack of ictal binding of [11C]-DHE to the brain
parenchyma suggests that the BBB remains intact for DHE
during migraine attacks. The efficacy of DHE in treating
an acute migraine attack may have a peripheral compo-
nent although some implicated structures remain outside
the BBB.
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